DRG Market Assessment reports

Clarivate Epidemiology’s coverage of gout comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed prevalence and incidence for each…

Biomarker-driven prescribing is vital in the treatment of key oncology indications, particularly non-small-cell lung cancer (NSCLC), colorectal cancer, and malignant melanoma. Treatment of these…

Many established therapies are available to treat rheumatoid arthritis (RA). Tumor necrosis factor-alpha (TNF-alpha) inhibitors are the most widely used class of agents after conventional disease-…

Diabetic macular edema (DME), a complication of diabetic retinopathy caused by persistently high blood sugar levels, can lead to vision loss if untreated. VEGF inhibitors such as Eylea, Lucentis,…

Clarivate Epidemiology’s coverage of prostate cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Several therapies from a range of drug classes are available to address the symptoms of narcolepsy; these symptoms include excessive daytime sleepiness (EDS) and cataplexy. Despite the availability…

Clarivate Epidemiology’s coverage of Gaucher disease (GD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. Symptoms range from general malaise to serious CNS and renal manifestations…

Clarivate Epidemiology’s coverage of breast cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of breast…

Clarivate Epidemiology’s coverage of breast cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of breast…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts of key breast cancer patient populations, covering 171 countries and more…

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s semaglutide SC (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have gained popularity in…